Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine HCl ER Extension in Prurigo Nodularis
NCT02174432Phase 3Completed
- Sponsor
- Trevi Therapeutics
- Start
- Aug 2015
- Primary completion
- Sep 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of nalbuphine in prurigo nodularis (PN), sponsored by Trevi Therapeutics. Started Aug 2015; status: completed.
02
Drugs
nalbuphine
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT02174432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02174432.